Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 11-12/2015

01.06.2015 | main topic

Drug safety aspects of herbal medicinal products

verfasst von: Dr. T. Wegener, B. Deitelhoff, A. Silber-Mankowsky

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 11-12/2015

Einloggen, um Zugang zu erhalten

Summary

There are numerous statements in the literature suggesting that the safety of herbal products or herbal medicinal products is inadequately considered. Despite the presence of risk, the potential is commonly underestimated as herbals are considered to be natural substances. It is necessary to consider the different categories of herbal products in the market. On one hand there are authorised herbal medicinal products (HMPs) which have adhered to the requirements to present data on quality, efficacy and safety. On the other hand there are products falling outside the use of marketing authorisations as for remedies. In the European Union (EU), HMPs are subject to an ambitious and comprehensive risk management system as for chemically defined drugs, which react effectively to risk concerns with scientific methods, as has been shown in the past. The established methods of pharmacovigilance and risk management favour the authorisation of herbal preparations for medicinal purposes as proprietary medicinal drugs.
Literatur
1.
Zurück zum Zitat Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23(6):854–9.PubMedCentralPubMedCrossRef Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23(6):854–9.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Jordan SA, Cunningham DG, Marles RJ. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol. 2010;243(2):198–216.PubMedCrossRef Jordan SA, Cunningham DG, Marles RJ. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol. 2010;243(2):198–216.PubMedCrossRef
3.
Zurück zum Zitat Mosihuzzaman M. Herbal medicine in healthcare–an overview. Nat Prod Commun. 2012;7(6):807–12.PubMed Mosihuzzaman M. Herbal medicine in healthcare–an overview. Nat Prod Commun. 2012;7(6):807–12.PubMed
4.
Zurück zum Zitat Shaw D, Graeme L, Pierre D, et al. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140:513–8. doi:10.1016/j.jep.2012.01.051. (Epub 2012 Feb 9. Review. PubMed PMID: 22342381).PubMedCrossRef Shaw D, Graeme L, Pierre D, et al. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140:513–8. doi:10.1016/j.jep.2012.01.051. (Epub 2012 Feb 9. Review. PubMed PMID: 22342381).PubMedCrossRef
5.
Zurück zum Zitat Kartal M. Intellectual property protection in the natural product drug discovery, traditional herbal medicine and herbal medicinal products. Phytother Res. 2007;21(2):113–9.PubMedCrossRef Kartal M. Intellectual property protection in the natural product drug discovery, traditional herbal medicine and herbal medicinal products. Phytother Res. 2007;21(2):113–9.PubMedCrossRef
6.
Zurück zum Zitat Neergheen-Bhujun VS. Underestimating the toxicological challenges associated with the use of herbal medicinal products in developing countries. Biomed Res Int. 2013;2013:804086. doi:10.1155/2013/804086. (Epub 2013 Sep 19).PubMedCentralPubMedCrossRef Neergheen-Bhujun VS. Underestimating the toxicological challenges associated with the use of herbal medicinal products in developing countries. Biomed Res Int. 2013;2013:804086. doi:10.1155/2013/804086. (Epub 2013 Sep 19).PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Pan S, Neeraj A, Srivastava KS, et al. A proposal for a quality system for herbal products. J Pharm Sci. 2013;102(12):4230–41. doi:10.1002/jps.23732. (Epub 2013 Oct 4).PubMedCrossRef Pan S, Neeraj A, Srivastava KS, et al. A proposal for a quality system for herbal products. J Pharm Sci. 2013;102(12):4230–41. doi:10.1002/jps.23732. (Epub 2013 Oct 4).PubMedCrossRef
8.
Zurück zum Zitat Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol. 2013;69(3):295–307. doi:10.1007/s00228-012-1353-z. (Epub 2012 Jul 29).PubMedCrossRef Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol. 2013;69(3):295–307. doi:10.1007/s00228-012-1353-z. (Epub 2012 Jul 29).PubMedCrossRef
9.
Zurück zum Zitat Walji R, Boon H, Barnes J, et al. Adverse event reporting for herbal medicines: a result of market forces. Healthc Policy. 2009;4(4):77–90.PubMedCentralPubMed Walji R, Boon H, Barnes J, et al. Adverse event reporting for herbal medicines: a result of market forces. Healthc Policy. 2009;4(4):77–90.PubMedCentralPubMed
10.
Zurück zum Zitat Schnabel K, Binting S, Witt CM, et al. Use of complementary and alternative medicine by older adults—a cross-sectional survey. BMC Geriatr. 2014;14:38. doi:10.1186/1471-2318-14-38.PubMedCentralPubMedCrossRef Schnabel K, Binting S, Witt CM, et al. Use of complementary and alternative medicine by older adults—a cross-sectional survey. BMC Geriatr. 2014;14:38. doi:10.1186/1471-2318-14-38.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Qu L, Zou W, Zhou Z, et al. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective. J Ethnopharmacol. 2014;156:107–14.PubMedCrossRef Qu L, Zou W, Zhou Z, et al. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective. J Ethnopharmacol. 2014;156:107–14.PubMedCrossRef
12.
Zurück zum Zitat Ruparel P, Lockwood B. The quality of commercially available herbal products. Nat Prod Commun. 2011;6(5):733–44.PubMed Ruparel P, Lockwood B. The quality of commercially available herbal products. Nat Prod Commun. 2011;6(5):733–44.PubMed
13.
Zurück zum Zitat Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women’s views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med. 2006;6:40.PubMedCentralPubMedCrossRef Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women’s views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med. 2006;6:40.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Samojlik I, Mijatović V, Gavarić N, et al. Consumers’ attitude towards the use and safety of herbal medicines and herbal dietary supplements in Serbia. Int J Clin Pharm. 2013;35(5):835–40. doi:10.1007/s11096-013-9819-3. (Epub 2013 Jul 3).PubMedCrossRef Samojlik I, Mijatović V, Gavarić N, et al. Consumers’ attitude towards the use and safety of herbal medicines and herbal dietary supplements in Serbia. Int J Clin Pharm. 2013;35(5):835–40. doi:10.1007/s11096-013-9819-3. (Epub 2013 Jul 3).PubMedCrossRef
15.
Zurück zum Zitat Marignani M, Gallina S, Di Fonzo M, et al. Use and safety perception of herbal remedies in patients with liver/biliary tract disorders: an Italian study. J Clin Gastroenterol. 2010;44 (Suppl 1):S54–7. doi:10.1097/MCG.0b013e3181e658bb.PubMedCrossRef Marignani M, Gallina S, Di Fonzo M, et al. Use and safety perception of herbal remedies in patients with liver/biliary tract disorders: an Italian study. J Clin Gastroenterol. 2010;44 (Suppl 1):S54–7. doi:10.1097/MCG.0b013e3181e658bb.PubMedCrossRef
16.
Zurück zum Zitat Ventola CL. Current issues regarding complementary and alternative medicine (CAM) in the United States: part 2: regulatory and safety concerns and proposed governmental policy changes with respect to dietary supplements. P T. 2010;35(9):514–22.PubMedCentralPubMed Ventola CL. Current issues regarding complementary and alternative medicine (CAM) in the United States: part 2: regulatory and safety concerns and proposed governmental policy changes with respect to dietary supplements. P T. 2010;35(9):514–22.PubMedCentralPubMed
17.
Zurück zum Zitat Directive. 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (as amended). Directive. 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (as amended).
18.
Zurück zum Zitat Directive. 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use (as amended). Directive. 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use (as amended).
19.
Zurück zum Zitat Zhang J, Wider B, Shang H, et al. Quality of herbal medicines: challenges and solutions. Complement Ther Med. 2012;20(1–2):100–6. doi:10.1016/j.ctim.2011.09.004. (Epub 2011 Nov 1).PubMedCrossRef Zhang J, Wider B, Shang H, et al. Quality of herbal medicines: challenges and solutions. Complement Ther Med. 2012;20(1–2):100–6. doi:10.1016/j.ctim.2011.09.004. (Epub 2011 Nov 1).PubMedCrossRef
20.
Zurück zum Zitat Ernst E, Pittler MH. Risks associated with herbal medicinal products. Wien Med Wochenschr. 2002;152(7–8):183–9.PubMedCrossRef Ernst E, Pittler MH. Risks associated with herbal medicinal products. Wien Med Wochenschr. 2002;152(7–8):183–9.PubMedCrossRef
21.
Zurück zum Zitat Naser B, Schnitker J, Minkin MJ, et al. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause. 2011;18:366–75.PubMedCrossRef Naser B, Schnitker J, Minkin MJ, et al. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause. 2011;18:366–75.PubMedCrossRef
22.
Zurück zum Zitat Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, et al. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol. 2011;10:249–59.PubMed Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, et al. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol. 2011;10:249–59.PubMed
23.
Zurück zum Zitat Committee on Herbal Medicinal Products (HMPC). Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). EMEA/HMPC/269258/2006 Rev. 1. 8 May 2007. Committee on Herbal Medicinal Products (HMPC). Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). EMEA/HMPC/269258/2006 Rev. 1. 8 May 2007.
24.
Zurück zum Zitat Henderson L, Yue QY, Bergquist C, et al. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54(4):349–56.PubMedCentralPubMedCrossRef Henderson L, Yue QY, Bergquist C, et al. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54(4):349–56.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Unger M. Pharmacokinetic drug interactions by herbal drugs: critical evaluation and clinical relevance. Wien Med Wochenschr. 2010;160:571–7.PubMedCrossRef Unger M. Pharmacokinetic drug interactions by herbal drugs: critical evaluation and clinical relevance. Wien Med Wochenschr. 2010;160:571–7.PubMedCrossRef
26.
Zurück zum Zitat Committee on Herbal Medicinal Products (HMPC). Community monograph on Hypericum perforatum L., herba. EMA/HMPC/101304/2008. 12 November 2009. Committee on Herbal Medicinal Products (HMPC). Community monograph on Hypericum perforatum L., herba. EMA/HMPC/101304/2008. 12 November 2009.
27.
Zurück zum Zitat Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011;31(5):490–502.PubMedCrossRef Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011;31(5):490–502.PubMedCrossRef
28.
Zurück zum Zitat Committee on Herbal Medicinal Products (HMPC). Assessment report on Ginkgo biloba L., folium (draft). EMA/HMPC/321095/2012. 28 January 2014. Committee on Herbal Medicinal Products (HMPC). Assessment report on Ginkgo biloba L., folium (draft). EMA/HMPC/321095/2012. 28 January 2014.
29.
Zurück zum Zitat Committee on Herbal Medicinal Products (HMPC). Community monograph on Ginkgo biloba L., folium (draft). EMA/HMPC/321097/2012. 28 January 2014. Committee on Herbal Medicinal Products (HMPC). Community monograph on Ginkgo biloba L., folium (draft). EMA/HMPC/321097/2012. 28 January 2014.
30.
Zurück zum Zitat Ketola RA, Viinamäki J, Rasanen I, et al. Fatal kavalactone intoxication by suicidal intravenous injection. Forensic Sci Int. 2015;249:e7–11. doi:10.1016/j.forsciint.2015.01.032. (pii: S0379-0738(15)00046 – 8).PubMedCrossRef Ketola RA, Viinamäki J, Rasanen I, et al. Fatal kavalactone intoxication by suicidal intravenous injection. Forensic Sci Int. 2015;249:e7–11. doi:10.1016/j.forsciint.2015.01.032. (pii: S0379-0738(15)00046 – 8).PubMedCrossRef
31.
Zurück zum Zitat Teschke R, Schwarzenboeck A, Hennermann K-H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol. 2008;20:1182–93.PubMedCrossRef Teschke R, Schwarzenboeck A, Hennermann K-H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol. 2008;20:1182–93.PubMedCrossRef
32.
Zurück zum Zitat Teschke R, Fuchs J, Bahre R, et al. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J Clin Pharm Ther. 2010;35:545–63.PubMedCrossRef Teschke R, Fuchs J, Bahre R, et al. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J Clin Pharm Ther. 2010;35:545–63.PubMedCrossRef
33.
Zurück zum Zitat Committee on Herbal Medicinal Products (HMPC). Public statement on Chelidonium majus L., herba. EMA/HMPC/743927/2010. 13 September 2011. Committee on Herbal Medicinal Products (HMPC). Public statement on Chelidonium majus L., herba. EMA/HMPC/743927/2010. 13 September 2011.
34.
Zurück zum Zitat Teschke R, Glass X, Schulze J, et al. Suspected greater celandine hepatotoxicity: liver-specific causality evaluation of published case reports from Europe. Eur J Gastroenterol Hepatol. 2012;24:270–80.PubMedCrossRef Teschke R, Glass X, Schulze J, et al. Suspected greater celandine hepatotoxicity: liver-specific causality evaluation of published case reports from Europe. Eur J Gastroenterol Hepatol. 2012;24:270–80.PubMedCrossRef
36.
Zurück zum Zitat Kelly WN, Arellano FM, Barnes J, et al. International society for pharmacoepidemiology, international society of pharmacovigilance. guidelines for submitting adverse event reports for publication. Drug Saf. 2007;30(5):367–73.PubMedCrossRef Kelly WN, Arellano FM, Barnes J, et al. International society for pharmacoepidemiology, international society of pharmacovigilance. guidelines for submitting adverse event reports for publication. Drug Saf. 2007;30(5):367–73.PubMedCrossRef
37.
Zurück zum Zitat Hung SK, Hillier S, Ernst E. Case reports of adverse effects of herbal medicinal products (HMPs): a quality assessment. Phytomedicine. 2011;18(5):335–43.PubMedCrossRef Hung SK, Hillier S, Ernst E. Case reports of adverse effects of herbal medicinal products (HMPs): a quality assessment. Phytomedicine. 2011;18(5):335–43.PubMedCrossRef
38.
Zurück zum Zitat Gardiner P, Adams D, Filippelli AC, et al. A systematic review of the reporting of adverse events associated with medical herb use among children. Glob Adv Health Med. 2013;2(2):46–55.PubMedCentralPubMed Gardiner P, Adams D, Filippelli AC, et al. A systematic review of the reporting of adverse events associated with medical herb use among children. Glob Adv Health Med. 2013;2(2):46–55.PubMedCentralPubMed
39.
Zurück zum Zitat Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database. Drug Saf. 2010;33(9):765–73.PubMedCrossRef Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database. Drug Saf. 2010;33(9):765–73.PubMedCrossRef
Metadaten
Titel
Drug safety aspects of herbal medicinal products
verfasst von
Dr. T. Wegener
B. Deitelhoff
A. Silber-Mankowsky
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 11-12/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-015-0370-9

Weitere Artikel der Ausgabe 11-12/2015

Wiener Medizinische Wochenschrift 11-12/2015 Zur Ausgabe